Appendix Table 2.

Estimated 48-week risks, risk differences and risk ratios of asymptomatic SARS-CoV-2 infection and mild COVID-19 by NRTI combination in HIV-positive individuals,^* CoVIHd Collaboration, Spain, February-December 2020

	Asymptomatic SARS-CoV-2 infection				Mild COVID-19
	No. events	Risks (95% CI), %	Risk Differences (95%CI), %	Risk Ratios (95%CI)	No. events	Risks (95% CI), %	Risk Differences (95%CI), %	Risk Ratios (95%CI)
TAF/FTC	206	1.00 (0.87, 1.12)	0	1.00	389	1.82 (1.64, 2.01)	0	1.00
TDF/FTC	77	1.15 (0.91, 1.45)	0.15 (−0.13, 0.44)	1.15 (0.87, 1.46)	155	2.21 (1.82, 2.58)	0.39 (−0.07, 0.76)	1.21 (0.97, 1.43)
ABC/3TC	133	1.06 (0.89, 1.26)	0.07 (−0.16, 0.29)	1.07 (0.85, 1.31)	274	2.16 (1.91, 2.42)	0.34 (0.01, 0.65)	1.19 (1.00, 1.38)
Other regimes	123	1.16 (0.96, 1.38)	0.17 (−0.06, 0.41)	1.17 (0.95, 1.44)	219	2.10 (1.84, 2.42)	0.28 (−0.04, 0.64)	1.15 (0.98, 1.37)

^*Adjusted via inverse probability weighting for age (in years, linear and quadratic terms), sex (male, female), transmission category (heterosexual, homo/bisexual, injecting drug use, other), country of origin (Spain, other), CD4 (<350, 350–500, >500 cells/mm3), and hypertension, diabetes, chronic renal disease, cardiovascular disease, and treatment with immunosuppressants or corticosteroids.